MiNK Therapeutics is a clinical stage biopharmaceutical company engaged in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Co.'s key product candidate, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy. In addition, Co. is developing a pipeline of allogeneic iNKT programs. Co.'s key programs include a CAR-iNKT program targeting B-cell maturation antigen (BCMA), which it refers to as BCMA-CAR-iNKT, and a tumor stromal targeting CAR-iNKT program, which it refers to as stromal target-CAR-iNKT. These programs are both in preclinical development. We show 8 historical shares outstanding datapoints in our coverage of INKT's shares outstanding history.
Understanding the changing numbers of INKT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like INKT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching INKT by allowing them to research INKT shares outstanding history
as well as any other stock in our coverage universe. |
Free INKT Email Alerts:
Video: Shares Outstanding Importance
